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Estimates of the prevalence of autoimmune diseases
range from 3 to 7%, and the treatment of a minority of
these patients with severe progressive disease is not sat-
isfactory. It has been recognized that the autoimmune
basis of human disease results from the failure of multiple
components of the immune system, but the most fre-
quently used criteria to establish the autoimmune nature of
a disease is the presence of defined reactions against
self-antigens as a major component in the pathophysiol-
ogy. This concept gave rise to the hypothesis that a stable
cure of autoimmune disease can only be expected if the
patient’s autoreactive immunocompetent cells are
replaced by cells that are not autoreactive. In this issue of
Arthritis Research, three therapeutic strategies are dis-
cussed that pursue this goal: allogeneic hematopoietic
stem–cell transplantation, autologous hematopoietic stem-
cell therapy following intensive suppression, and intense
immune suppression alone [1–3].
Work in experimental animals with induced autoimmune
disease convincingly showed that ongoing disease could
be cured by bone marrow transplants from healthy
animals. Pertinent to the translation into clinical practice of
such treatment are the findings of Van Bekkum and
coworkers (reviewed in [3]) that autologous stem-cell
therapy is as effective as allogeneic transplantation. These
observations were made in mice with adjuvant arthritis and
experimental allergic encephalomyelitis.
During the past decade multiple case histories have
described long-term remissions and possible cures of
autoimmune disease after allogeneic bone marrow trans-
plantation. However, the current morbidity and mortality
related to this treatment are unacceptable for most auto-
immune diseases. Therefore, autologous stem-cell therapy
after intense immune suppression received considerable
attention because of the lower toxicity and greater
feasibility. A variety of diseases were selected, including
rheumatoid arthritis, juvenile chronic arthritis, systemic scle-
rosis, systemic lupus erythematosus, Crohn’s disease and
multiple sclerosis. The results so far, both with respect to
efficacy and toxicity observations, are encouraging, but
remissions rather than cures have been obtained.
Another unresolved issue is whether stem-cell therapy is
indeed crucial to obtain efficacy in a patient treated with
intense immune suppression. The problem of late onco-
genicity after severe immune suppression in young
patients should also be taken into account. The central
question is of course whether intense immune suppres-
sion followed by stem-cell rescue is capable of achieving
tolerance. This goal has been achieved in experimental
work but has not yet been demonstrated in the clinic. To
further develop this therapeutic strategy more information
on the correlation between clinical responses and
immunological sequelae after intervention is urgently
needed. It cannot be excluded that intense immune abla-
tion followed by autologous stem-cell rescue cannot eradi-
cate autoreactive memory lymphocytes, and that
allogeneic bone marrow transplantation is necessary to
achieve this goal. The recent introduction of myelosup-
pressive regimens that exploit the presence of chimaeric
myelopoiesis, as well as the usefulness of donor lympho-
cyte immune effects, is an additional promising develop-
ment in treatment of malignant and nonmalignant
diseases. The possibility of a graft anti-autoimmunity effect
may be advantageous in the maintenance of remission.
Further work should involve comparative studies that may
reveal whether the results of these new strategies are
superior to those of conventional therapy. Such work
should be performed in close collaboration between multi-
ple medical disciplines to address the fundamental ques-
tions associated with this therapeutic strategy.http://arthritis-research.com/content/2/4/268
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